Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Revenue of Prelude Therapeutics Incorporated (PRLD)
Revenue in 2023 (TTM): $
According to Prelude Therapeutics Incorporated's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Prelude Therapeutics Incorporated
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,169,000 | $-131,108,000 | $-121,832,000 | $-121,832,000 |
| 2022 | $ | $-3,042,000 | $-123,540,000 | $-115,438,000 | $-107,336,000 |
| 2021 | $ | $-2,243,000 | $-113,735,000 | $-111,694,000 | $-110,779,000 |
| 2020 | $ | $-542,000 | $-58,221,000 | $-56,929,000 | $-56,929,000 |
| 2019 | $ | $-382,000 | $-27,727,000 | $-27,570,000 | $-27,570,000 |
| 2018 | $ | $-149,000 | $-14,826,000 | $-14,680,000 | $-14,680,000 |